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ABSTRACT Lymphangioleiomyomatosis is a rare disease characterised by cystic destruction of the lung,
lymphatic abnormalities and abdominal tumours. It affects almost exclusively females and can occur
sporadically or in patients with tuberous sclerosis complex.
In the past decade remarkable progress has been made in understanding of the pathogenesis of this disease
leading to a new therapeutic approach. This review summarises recent advances regarding pathogenic
mechanisms and clinical manifestations, and highlights the current and the most promising future
therapeutic strategies.
@ERSpublications
Recent advances in pathogenesis, clinical manifestations and therapeutic strategies of
lymphangioleiomyomatosis http://ow.ly/Rbmlh
Copyright ©ERS 2015
Previous articles in this series: No. 1: Collard HR, Bradford WZ, Cottin V, et al. A new era in idiopathic pulmonary
fibrosis: considerations for future clinical trials. Eur Respir J 2015; 46: 243–249. No. 2: Ryerson CJ, Cottin V, Brown KK,
et al. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J 2015; 46: 512–520.
Received: March 13 2015 | Accepted after revision: July 11 2015 | First published online: Sept 24 2015
Conflict of interest: None declared.
Eur Respir J 2015; 46: 1471–1485 | DOI: 10.1183/13993003.00412-2015 1471
SERIES
RARE DISEASES AND ORPHAN DRUGS
Introduction
Lymphangioleiomyomatosis (LAM) is a multisystem disease affecting almost exclusively women, it is
characterised by proliferation of abnormal smooth muscle-like cells (LAM cells), leading to the formation of
lung cysts, fluid-filled cystic structures in the axial lymphatics (i.e. lymphangioleiomyomas) and
angiomyolipomas, which are benign tumours usually found in the kidneys [1, 2]. It can be sporadic or occur
in women with tuberous sclerosis complex (TSC), an autosomal dominant syndrome characterised by
cerebral calcifications, seizures, mental retardation and hamartomatous lesions in various organs [3, 4].
Sporadic LAM is uncommon in men [5–7]; however, cystic change suggestive of LAM has been recognised
in 13% and 38% of men with TSC in two different retrospective studies, although LAM seems to be milder
in men compared with women with TSC [8, 9]. LAM was reported to affect about a third of women with
TSC [10, 11], but recent findings in a large cohort of patients suggest that the prevalence of cystic changes
consistent with LAM on computed tomography (CT) scans is higher and increase with age (up to 80% of
subjects aged >40 years) [12]. TSC occurs in one in 5800 births, and sporadic LAM has a prevalence
estimated to be between 3 and 7.8 per million women [13, 14]. Despite the rarity of the disease, in the past
decade, remarkable advances have been made regarding clinical presentation, pathogenetic mechanisms and
therapeutic possibilities, mostly thanks to data collected worldwide by LAM associations, national registries
and referral centres. In 2010, guidelines for the diagnosis, assessment and treatment of LAM were published
by the European Respiratory Society (ERS) LAM Task Force. These guidelines defined diagnostic criteria and
highlighted management approaches including follow-up and available treatment and its complications [15].
LAM cells and pathogenesis of the disease
LAM results from the proliferation of LAM cells, which include myofibroblast-like, spindle-shaped cells
and epithelioid-like cells that express smooth muscle-specific proteins [16, 17]. The epithelioid cells also
express oestrogen and progesterone receptors [17–19]. Glycoprotein gp100, a marker of melanoma cells
and immature melanocytes, is found in LAM cells, and reacts with monoclonal HMB-45 [20, 21]. The
spindle-shaped cells also express proliferating cell nuclear antigen, a marker of DNA synthesis and cell
proliferation [20]. More recently, CD44v6, a glycoprotein that binds hyaluronic acid and is associated
with metastatic cancers, has also been found on the LAM cell surface [22]. Osteopontin, a regulator of
CD44 splicing, is elevated in serum, and matrix metalloproteinases (MMPs) are found in the LAM
lung nodule and may be responsible for lung destruction [22, 23]. CD44v6 could be involved in
pathogenesis of LAM by enabling LAM cells to adhere to the extracellular matrix, thereby facilitating
their metastasis.
Indeed, several findings indicate that LAM cells can metastasise. Identical TSC2 mutations were found in
lung lesions and angiomyolipomas from the same patient with sporadic LAM, and recurrent LAM cells of
recipient origin were detected after lung transplantation in the donor lung [24–26]. LAM cells have been
found in the blood, urine and chylous fluids of some LAM patients, demonstrating that LAM cells can
leave primary lesions and disseminate through the lymphatics or blood vessels [27].
Understanding the genetic basis of LAM has been pivotal to progress in pathogenesis and potential
therapeutic approaches. In the early 2000s, it was confirmed that LAM is characterised by mutations in
the tuberous sclerosis genes TSC1 and, much more frequently, TSC2 causing the loss of function of
either TSC1 or TSC2 gene products, which are known as hamartin and tuberin, respectively [28–31].
Tuberin is involved in the cell cycle and in cell growth and proliferation; hamartin is thought to have a
role in the reorganisation of the actin cytoskeleton by inducing an increase in Rho-GTP levels and by
binding activated ezrin/radixin/moesin proteins [2]. In vivo, hamartin and tuberin are part of a
heterotrimer acting upstream of the intracellular serine/threonine kinase mammalian/mechanistic target
of rapamycin (mTOR), whose major function is regulation of cell growth and proliferation mediated by
growth factors, energy and stress signals. There are two complexes involving mTOR: mTORC1, which
includes raptor (regulatory-associated protein of mTOR) and is sensitive to the mTOR inhibitor
rapamycin; and mTORC2, which contains rictor (rapamycin-insensitive companion of mTOR) and is
relatively insensitive to rapamycin [32, 33]. The hamartin–tuberin complex negatively regulates
mTORC1 by stimulating GTP hydrolysis by the protein Rheb (Ras homolog enriched in brain) [34–36].
Inhibition of the hamartin–tuberin complex by growth factors through the mitogen-activated protein
kinase (MAPK) and insulin-signalling pathways causes accumulation of active Rheb–GTP, which
stimulates mTORC1 [35–38]. mTORC1 phosphorylates ribosomal S6 kinase and eukaryotic initiation
factor 4E-binding protein, leading to enhanced translation [39]. The MAPK signalling pathway can
activate mTORC1 without involving the hamartin–tuberin complex via RSK-catalysed phosphorylation
of raptor, a component of the mTORC1 complex [40]. The insulin-signalling pathway can also activate
mTORC1 directly by Akt-catalysed phosphorylation of PRAS40, an inhibitor of mTORC1, thereby
relieving the inhibition. mTORC1 is a key inhibitor of autophagy via ULK1, and autophagy levels are
low in TSC-deficient LAM cells [41–43].
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Although most biochemical and signalling effects in cells lacking TSC1 or TSC2 products are thought to
occur through activation of mTORC1, in the past few years mTORC1-independent mechanisms have been
defined. Non-canonical, still less well-known functions of the hamartin–tuberin complex and Rheb include
regulation of the cytoskeleton and RhoA via hamartin or TORC2, regulation of the primary cilium, and
regulation of cellular differentiation and proliferation via B-Raf and Notch [44–50]. The hamartin–tuberin
complex positively regulates mTORC2, which may have a role in actin dynamics, through activation of
protein kinase Cα and Rac and Rho GTPases [51].
A Rheb-independent function of the hamartin–tuberin complex may be regulation of MMPs. MMPs are
overexpressed in cells lacking TSC1/TSC2, and this overproduction is not affected by either Rheb
knockdown or rapamycin [52]. MMPs have been implicated in the pathogenesis of LAM; they are present
in LAM lesions, and are elevated in the blood and urine of patients with LAM [23, 53].
Recently, adipocyte phospholipase A2 (AdPLA2), a rate-limiting enzyme in the production of
prostaglandins, has been shown to be upregulated in LAM lung nodules. This overexpression is TSC2
dependent and rapamycin insensitive in cell culture models [54]. This finding suggests that production of
prostaglandins modulated by AdPLA2 may play a role in promoting tumorigenesis and disease
progression in TSC and LAM.
Oestrogens are involved in the pathogenesis of LAM by interactions with signalling events in LAM cells. A
role of oestrogens in LAM is suggested by its female predominance, its frequent occurrence during
childbearing age, reported worsening of lung disease following the administration of oestrogens [55] or
during pregnancy [56], and the presence of oestrogen receptors and progesterone receptors in LAM cells
and angiomyolipomas [14, 57, 58]. Decline in lung function is greater in pre-menopausal women than in
post-menopausal women [59].
Oestrogen promotes the proliferation of Tsc-null rat ELT3 leiomyoma-derived cells in vitro [60]. In
experimental animals, oestradiol has been shown to stimulate growth of human angiomyolipoma TSC2+/-
cells, which was associated with activation of p42/44 MAPK [61]. Oestrogen has been shown to promote
the survival and pulmonary metastasis of Tsc2−/− ELT3 cells in mice, which was associated with activation
of MAPK and inhibited by the MAPK/ERK kinase (MEK) inhibitor CI-1040 [62]. More recently, it has
been found that oestrogen stimulates a strong and biphasic activation of ERK2 and transcription of the
late response-gene Fra1, which is involved in the oestrogen-stimulated invasive phenotype of LAM
patient-derived cells [63]. Activated TORC1/S6K1 signalling enhances the efficiency of translation of Fra1
mRNA regulated by the oestrogen–ERK2 pathway. These results demonstrate integrated signalling of
mTOR and oestrogen–ERK pathways in promoting migration and invasion by these cells, and suggest a
rationale for a potential combination therapy [63].
Moreover, in lung-derived cells from an explant from a LAM patient, MMP-2 activity was increased by
oestrogen receptors, promoting cell invasiveness, and doxycycline, an antibiotic with anti-MMP activity,
inhibited this effect. These findings suggest an oestrogen–MMP-driven process involved in lung
destruction and LAM cell metastasis [64].
LAM: a neoplasm
LAM was first defined as a “tumour-like” lesion by the World Health Organization classification of lung
tumours in 1999 [65]. Subsequently, LAM has been included among the “perivascular epithelioid cell
tumours”. These are mesenchymal tumours composed of histologically and immunohistochemically distinctive
perivascular epithelioid cells, which present a distinct immunophenotypic profile, with the coexpression of
myogenic and melanocytic markers, such as gp100 (a protein recognised by the HMB-45 monoclonal
antibody), Melan-A/Mart1, MiTF, α-smooth muscle actin and, less often, desmin [66]. Several genetic and
cellular findings have shown that LAM cells exhibit the features and behaviours of a neoplasm [67]. The
evidence of loss of heterozygosity for TSC genes in the lung, kidney and lymphatic lesions of patients with
LAM is consistent with a tumour suppressor gene. Moreover, identical TSC mutations found in the
angiomyolipomas, lymph nodes and lungs from the same patients are consistent with seeding from a common
source [29]. Recurrence of recipient LAM cells in transplanted lungs, and the presence of LAM cells in the
blood and other body fluids suggest that LAM cells exhibit metastatic behaviour [24–27]. However, the source
of LAM cells has not been identified. Angiomyolipomas, the uterus and the lymphatic system have been
considered as possible sources. The TSC mutations that occur in LAM result in inappropriate, constitutive
signalling through the mTOR pathway, which controls protein translation and is activated in human cancers
[68]. Inappropriate proliferation and invasion, angiogenesis and lymphangiogenesis, and protease-driven
matrix degradation are other features that LAM shares with neoplastic processes [1, 46, 69–71].
Even given the absence of atypia, the low grade proliferation, the questions regarding LAM cell origin and
the psychological concerns of patients about such a label, currently, LAM should be considered a chronic
neoplastic disease.
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Clinical presentation, natural history and prognosis
Most of the early clinical conclusions about LAM were based on case reports. Subsequently, clinical papers
based on larger numbers of patients appeared, drawing a new and more complete clinical picture of the
disease. Data from clinical studies during the past decade have revealed quite different clinical phenotypes
[1, 5, 72]. Although the average age at LAM diagnosis in multiple series is ∼35 years [73], LAM was found
to occur not only in childbearing women but also in those of post-menopausal age, and the life
expectancy of patients can span decades [1, 74]. A large survey (n=328), based on data collected from
patients in the database of the US LAM Foundation and LAM Action in the UK, found that more women
over the age of 40 years were being diagnosed with LAM, with the result that the mean age at diagnosis
was increasing over time [75]. At diagnosis, women with TSC-LAM are younger and have less impaired
lung function compared with those with sporadic disease [5, 73]. The average time from the onset of
symptoms related to LAM to the definitive diagnosis of the disease ranges from 2 to 6 years [5, 75].
The most common respiratory symptoms at presentation are dyspnoea (over 70%), pneumothorax (∼50%),
which is often recurrent, and chylous pleural effusions [5, 76, 77]. On CT scans, the characteristic
pulmonary abnormalities are well circumscribed, round and thin-walled cysts that are scattered in a
bilateral, roughly symmetric pattern, without any lobar predominance (figs 1 and 2). Extrapulmonary
presentations are intra-abdominal haemorrhage or the finding of an abdominal mass due to
lymphadenopathy, lymphangioleiomyoma and/or angiomyolipoma [5, 74, 78, 79]. Lymphangioleiomyomas
are cystic tumours occurring primarily in the abdomen, retroperitoneum and pelvis, and can been found in
up to 10% of patients [72]. They have a distinctive radiological appearance and may change in size during
the day [79, 80]. Lymphangioleiomyomas may be asymptomatic or present with nausea, abdominal
distension or pain, peripheral oedema, urinary symptoms, or as an acute abdomen [80–82].
Angiomyolipomas are benign tumours that occur mainly in the kidneys (fig. 3). Data from recent studies
indicate angiomyolipomas occur in up to 100% of patients with TSC-LAM and in up to 50% of those with
sporadic LAM [5, 12, 83, 84]. Angiomyolipomas are often asymptomatic, but larger tumours can cause
bleeding, which has been treated with selective embolisation or surgery [85]. Patients with TSC commonly
have multiple and large angiomyolipomas. Previous series suggested that angiomyolipomas in TSC grow
more rapidly and are more prone to complications than angiomyolipomas in patients without TSC [86–88].
According to the International Tuberous Sclerosis Complex Consensus Conference, in patients with TSC,
the progression of angiomyolipoma should be assessed every 1–3 years by magnetic resonance imaging of
the abdomen, and intervention is recommended for asymptomatic tumours larger than 3 cm [89]. ERS
guidelines on LAM recommend screening for angiomyolipomas in all patients with LAM or suspected
LAM, and suggest that asymptomatic renal angiomyolipomas smaller than 4 cm should be followed by
yearly ultrasound, while tumours larger than 4 cm or with renal aneurysms >5 mm in diameter should be
checked twice yearly and considered for treatment because of the higher risk of complications [15].
A recent study in a large cohort of patients with sporadic LAM (n=53) showed that angiomylipomas are
prone to growth and haemorrhage, present at any time during the clinical course, and tumour presence
cannot be predicted by functional parameters or other clinical characteristics such as age at respiratory
presentation [83]. No significant difference in the incidence of bleeding or the need for intervention was
found between patients with and without TSC. The mean rate of growth for an angiomyolipoma in
sporadic LAM was 1.8 mm per year. Although no overall relationship between tumour size and growth
was shown, there was a trend toward larger tumours growing more rapidly [83]. Despite some limitations,
due to the retrospective nature of some data, the use of some surrogate end-points such as referral for an
intervention and the use of different imaging modalities, the study by YEOH et al. [83] suggests that
angiomyolipomas in sporadic LAM have a similar risk of bleeding to those with TSC and require adequate
a) b)
FIGURE 1 a, b) High-resolution chest computed tomography images of a patient with lymphangioleiomyomatosis,
showing round-shaped, thin-walled cysts distributed diffusely throughout the lungs.
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screening and a closer follow-up than previously suggested by ERS guidelines. The authors propose that
imaging should be performed every 12 months for tumours between 11 and 30 mm in diameter, and every
6 months for tumours >30 mm. In the latter situation a therapeutic intervention should be considered.
Irrespective of tumour size, the presence of bleeding or the suspicion of a malignancy requires intervention
[15, 85, 89]. Embolisation or nephron-sparing surgery can be performed in symptomatic or bleeding
tumours depending upon local expertise; nephrectomy should be avoided because of the high incidence of
complications and increased risk of future renal insufficiency [15, 89]. A biopsy and, eventually, a
conservative surgical intervention are necessary when a malignant lesion is suspected [15, 89].
The most frequent pulmonary function abnormalities in LAM are airflow obstruction and decreased lung
diffusion capacity [5, 90, 91]. ∼30% of patients have normal tests. Airflow obstruction is present in over
60% of patients and reduced diffusing capacity can be seen in up to 80% of patients [5, 90, 92]. Airflow
a) b)
FIGURE 2 a, b) High-resolution chest computed tomography images of a patient with biopsy-proven
lymphangioleiomyomatosis, showing a few bilateral, round-shaped, thin-walled cysts.
FIGURE 3 Abdominal contrast-enhanced computed tomography image of a patient with tuberous sclerosis
complex-lymphangioleiomyomatosis, showing multiple intracortical (white asterisk) and one extracortical
(white hash) right renal angiomyolipomas with a fatty, low-density component.
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obstruction is reversible in 25–30% of LAM patients [90, 93]. Diffusing capacity of the lung for carbon
monoxide (DLCO) and forced expiratory volume in 1 s (FEV1) have been shown to correlate with disease
severity as assessed by CT, LAM histology score and exercise testing [59, 91, 94–96].
The annual decline in lung function in untreated patients is variable. Mean annual decline in FEV1 has
been reported as 60–120 mL per year in different retrospective studies of referral centres or national
cohorts [1, 97, 98]. Two recent clinical trials about use of sirolimus and doxycycline showed a mean
ΔFEV1 post-bronchodilator in the placebo group of −134 mL (in the 12 month study period) and
−90.3 mL per year, respectively [99, 100].
Prognostic information in LAM has changed over time. Early retrospective studies based on small numbers
reported a 5- and 10-year mortality of 40 and 80%, respectively [101, 102]. More recent studies showed that
LAM has a slower progression and a better prognosis than previously thought, even if the disease course varies
widely in individual patients. Mortality at 10 years has been estimated to be 30% from the time of lung biopsy
[94] and ∼10–20% from the onset of symptoms [1, 74, 94]. Recently, in a large cohort of patients (n=401)
with long-term follow-up [103], an estimated 10-year transplant-free survival of 86% was observed; the
median transplant-free survival for the overall cohort was 29 years from the time of onset of symptoms, and
23 years from the time of diagnosis. No statistically significant difference between the hormonally treated and
untreated subgroup was found when adjusted for the severity of disease (i.e. oxygen use). Even if the results
may be biased by the lack of data from pulmonary function tests, the conclusions of the study about survival
are consistent with estimates from previous recent cohorts [103]. Although LAM has a heterogeneous course
and often unpredictable outcome, in the past few years some clinical characteristics have been found to be
associated with prognosis. Previously it was found that obstructive functional abnormalities, as measured by
reduction in the FEV1/forced vital capacity (FVC) ratio and hyperinflation, manifested as an increase in total
lung capacity at presentation, and were associated with a worse prognosis and reduced survival [104]. A
subsequent study on a larger cohort of patients with LAM analysed predictors of decline in pulmonary
function tests for a mean duration of 5 years [59]. Initial lung function and age were found to predict
functional decline. The rate of decline in FEV1 was inversely correlated with the initial DLCO and age: rates of
decline in FEV1 were lower in older patients and in patients with higher DLCO and FEV1. Patients with
reversible obstruction to bronchodilators appeared to have a greater predominance of proliferative lung lesions
[59], and bronchodilator responsive airflow obstruction has been associated with an accelerated decline in lung
function [92]. A report from Japan suggests that presentation with pneumothorax is associated with younger
age and a more favourable prognosis than presentation with dyspnoea (10-year survival rate of 89% and 47%,
respectively) [91]. In accordance with these results, the recent study by OPRESCU et al. [103] showed that
patients who presented with dyspnoea or cough had a worse prognosis compared with the subgroup who
presented with pleural disease (pneumothorax or pleural effusion) or other presentations. In this report, age at
presentation, the need for supplemental oxygen therapy and reported weight loss were independent predictors
of survival; older age at presentation was associated with improved survival, whereas the need for
supplemental oxygen therapy and reported weight loss were associated with a shorter survival. The authors
suggest that the mechanism for the association between weight loss and worse prognosis might follow the
model established for chronic obstructive pulmonary disease [105]. Table 1 summarises the prognostic factors.
Biomarkers of LAM
Vascular endothelial growth factor-D
Vascular endothelial growth factor-D (VEGF-D) is a lymphangiogenic growth factor that induces
formation of lymphatics and promotes the spread of tumour cells to lymph nodes. Serum levels of
TABLE 1 Prognostic clinical characteristics in lymphangioleiomyomatosis
Worse prognosis
Dyspnoea as presenting feature
Weight loss
Supplemental oxygen therapy
Reversible airflow obstruction
High VEGF-D
Better prognosis
Pneumothorax as presenting feature
Older age at diagnosis
Higher FEV1, DLCO at diagnosis
VEGF-D: vascular endothelial growth factor-D; FEV1: forced expiratory volume in 1s; DLCO: diffusing
capacity of the lung for carbon monoxide.
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VEGF-D have been shown to be elevated in patients with sporadic LAM as compared with healthy
controls, and higher levels of serum VEGF-D were associated with greater loss of pulmonary function as
measured by DLCO/alveolar volume and FEV1/FVC, all suggesting that VEGF-D influences
lymphangiogenesis in LAM [106].
YOUNG et al. [107] first reported that serum VEGF-D levels were higher in LAM than in similar cystic or
chylous lung diseases, indicating that it might be a clinically useful diagnostic test for differential
diagnosis. A subsequent study by GLASGOW et al. [108], comparing VEGF-D levels in patients with
sporadic LAM (n=111) to those in healthy volunteers, confirmed that serum VEGF-D levels were higher
in patients with LAM. However, when patient samples were grouped based on the extent of lymphatic
extrapulmonary involvement (e.g. lymphangioleiomyomas or adenopathy) the difference was maintained
only for patients with LAM and lymphatic involvement. In this subgroup of patients, higher VEGF-D
levels were associated with a higher severity score on CT scan analysis and lower DLCO. These results
suggest that VEGF-D levels might be a measure of lymphatic involvement in LAM [108].
The validity of serum VEGF-D levels as a diagnostic test was confirmed in a prospective study showing
that a serum VEGF-D level higher than 800 pg·mL−1 in a woman with typical changes on high-resolution
CT is diagnostically specific for LAM, reducing the need for lung biopsy, and is associated with pulmonary
LAM in women with TSC [109]. The study did not show a relationship between serum VEGF-D levels
and the use of supplemental oxygen or FEV1 in the group of patients with LAM. In this study, pulmonary
function testing was not performed at the same time as the determination of VEGF-D. Serum VEGF-D
levels higher than 800 pg·mL−1 plus findings of compatible cystic change on high-resolution CT were
considered as diagnostic in defining the inclusion criteria for the Multicenter International
Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial [99].
Recently, the results of an analysis of data from the MILES trial to assess the usefulness of serum VEGF-D
levels as a marker of severity and therapeutic response showed that VEGF-D levels at baseline were higher
in patients who needed supplemental oxygen and in those who used a bronchodilator [110]. Moreover,
baseline VEGF-D levels were associated with markers of airflow obstruction and hyperinflation. Median
serum VEGF-D concentrations fell significantly from baseline at 6 and 12 months in the sirolimus group
but remained almost stable in the placebo group. In addition, in the sirolimus group each one-unit
increase in baseline log(VEGF-D) was associated with a 5 mL per month increase in FEV1 and a 14 mL
per month increase in FVC. These results confirm that VEGF-D is a useful biomarker that correlates with
disease severity and treatment response. In addition, the results suggested that serum VEGF-D
concentrations might also be useful for stratification of patients for trials and reduce the number of
patients needed to adequately power studies.
The mechanisms by which VEGF-D might affect disease severity in LAM is, as yet, unknown. LAM
nodules are known to contain VEGF-D. LAM cells might disseminate via lymphangiogenesis-mediated
shedding of LAM cell clusters, a process that might result in the development of new lesions in the lung
and elsewhere [67, 111].
Other biomarkers
MMPs are components of the extracellular matrix involved in lung remodelling and lymphangiogenesis [112].
MMPs have also been associated with LAM lesions, and LAM nodules have been shown to contain MMP
activators and inhibitors [42, 113–115]. Levels of tissue inhibitor of metalloproteinase-3, which inhibits some
MMPs, are low in LAM lesions compared with normal lung parenchyma, which may facilitate MMP-catalysed
proteolysis [114]. Serum levels of MMP-9 are higher in patients with LAM than in normal subjects, suggesting
that excessive production of MMPs by LAM cells may contribute to lung destruction [47].
Monitoring of urinary MMPs in LAM could be of value in assessing disease severity and response to
therapeutic agents. Urinary levels of MMPs were reported to become undetectable after 3 months of
treatment with doxycycline, an inhibitor of MMPs, in a patient with severe LAM [116]. Moreover, there
was a significant reduction in urinary MMP-9 levels and serum MMP-2 levels following treatment with
doxycycline in an open-label, single-arm, interventional clinical trial [117].
Treatment
Hormonal treatment
In the past, various hormonal strategies have been used in the treatment of LAM. Effects of bilateral
oophorectomy are controversial, and there is no objective evidence of improvement with anti-oestrogen
therapy [118, 119]. Improvement following use of gonadotrophin-releasing hormone (GnRH) analogues
has been reported, but other studies were inconclusive and no controlled clinical trials on GnRH
analogues have been conducted [120–123]. Although progesterone became the standard of care after a
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series of case reports and clinical studies [124, 125], there are no clinical trials of its use in LAM.
Retrospective studies have shown dissimilar results. JOHNSON and TATTERSFIELD [97] found a significant
reduction in the rate of decline of DLCO in patients treated with progesterone compared with untreated
patients. Another retrospective study of a large cohort of patients with LAM (n=275) showed no difference
in the overall yearly rates of decline of FEV1 and DLCO between patients who were treated with oral or
intramuscular progesterone and patients who did not receive progesterone [59]. Because of the
inconclusive results and the lack of controlled clinical trials, at the moment, hormonal treatment in
patients with LAM should be discouraged.
mTOR inhibitors
The mTOR inhibitors, sirolimus (also known as rapamycin) and everolimus, block mTOR-mediated
activation of downstream kinases, inhibiting proliferation and growth of LAM cells [34, 126].
Inhibitors of mTOR have been proven to be effective in the treatment of patients with LAM and TSC. The
Cincinnati Angiomyolipoma Sirolimus Trial (CAST) was a pilot study that showed a significant reduction of
angiomyolipoma volume after 1 year of treatment with sirolimus and an increase in functional parameters in
the subgroup of patients with LAM [127].
The MILES trial, a larger randomised placebo-controlled trial on the safety and efficacy of sirolimus in
patients with LAM and moderate functional impairment, showed a stabilisation of lung function,
expressed as FEV1, during the 12-month treatment period [99]. After discontinuation of treatment, the
decline in lung function resumed in the sirolimus group and paralleled that in the placebo group.
Moreover, during the treatment period, the sirolimus group showed improvement from baseline to
12 months in measures of FVC, quality of life and serum VEGF-D. No difference was found in 6-min
walking distance (6MWD) and DLCO between the two groups [99]. During the treatment period, the
serum level of sirolimus was maintained between 5 and 15 ng·mL−1. Sirolimus was associated with an
increased frequency of adverse events, of which the most common were mucositis, gastrointestinal events,
hypercholesterolaemia, acneiform rash and swelling in the lower extremities. However, the rates of serious
adverse events were similar in the two study groups.
Patients with chylous effusions were not included in the MILES trial because of the potential effects on
pulmonary function. An observational study of patients with rapidly progressive LAM and chylous
complications showed that therapy with sirolimus was also associated with a reduction in the size of
chylous effusions and lymphangioleiomyomas, leading to almost complete resolution of these conditions
[128]. A case of resolution of lung infiltrates on CT scan, with improvement in symptoms and functional
parameters, and resolution of respiratory failure after treatment with sirolimus has been reported in a
woman with LAM who had already undergone bilateral pleurodesis [129]. The authors concluded that
decreased LAM lesions along the thoracic duct led to partial relief of the obstruction, with improved chyle
flow and decreased leakage into the lung. Reduction in the size of lung nodules and LAM cell infiltrates
involving or surrounding the airways probably accounts for the stabilisation or improvement in lung
function associated with sirolimus therapy.
Drug toxicity and development of resistance are potential problems related to therapy with mTOR inhibitors.
Recently, YAO et al. [130] published the results of a study on the effects of sustained treatment with
sirolimus, in a cohort of 38 patients with LAM, including patients with lymphatic involvement. Treatment
with sirolimus for a period of ∼3.5 years stabilised lung function by slowing declines in FEV1 and DLCO and
changes in lung volume occupied by cysts. No evidence of worsening was seen in terms of exercise tolerance
or exercise capacity [130]. In a subgroup of 12 patients followed for ∼5 years, the study showed both a
reduction in functional decline and changes in cyst size. The prevalence of adverse events associated with
sirolimus was high; however, most patients were able to continue therapy with only brief interruptions [130].
Although the high number of patients with lymphatic involvement in this cohort may not be representative
of the entire LAM population, these results suggest that the therapeutic effects of sirolimus on functional
decline and cystic changes are sustained over time with a manageable and acceptable spectrum of toxicities,
at least in the population of patients who are likely to need therapeutic intervention.
Another current concern about LAM therapy is whether lower doses of sirolimus could be used to maintain
therapeutic effects and reduce toxicity. A Japanese retrospective, observational study of 15 patients with LAM
before and after therapy with serum levels of sirolimus <5 ng·mL−1 throughout the treatment period showed
an improvement in the annual rate of change in FVC and FEV1 in the eight patients without chylous
effusions. All but one of the remaining seven patients with chylous effusions experienced complete
resolution of chylothorax and significant reduction of chylous ascites [131]. Except for a patient who
developed a slight increase in parenchymal opacity on chest radiography and a patient who developed
Aspergillus infection, the adverse events were mostly low grade. Despite the low-dose regimen, the incidence
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of adverse events was similar to that reported previously. Only hypercholesterolaemia was not observed in
the study. This result may be explained by the Asian study population, as suggested by a previous subgroup
analysis of the MILES trial [132] showing different adverse events between American and Japanese
participants. Although the retrospective, non-controlled design of the study does not allow definitive
conclusions, the results suggest that even at a blood trough level of <5 ng·mL−1, sirolimus might be clinically
effective and safe. Prospective studies comparing conventional and low-dose sirolimus are necessary.
Everolimus is a second generation mTOR1 inhibitor, which has been proven to be effective in reducing the
size of giant cell astrocytomas in patients with TSC [133, 134]. Recently, the EXIST-2 trial proved the
efficacy of everolimus in decreasing the size of renal angiomyolipomas in patients with TSC or LAM [135].
In addition, patients on everolimus had a significantly higher skin lesion response rate than patients on
placebo. Adverse events were consistent with the known everolimus safety profile. Stomatitis,
nasopharyngitis, acne-like skin lesions, headache, cough and hypercholesterolaemia were the most common
adverse events. Infection occurred in 65% of patients on everolimus without grade 4 infectious events. The
results of an exploratory, open-label, non-randomised, within-subject dose escalation trial of everolimus in
patients with LAM have just been published [136]. Primary end-points were safety and tolerability,
pharmacokinetics, and VEGF-D levels; secondary end-points were measures of lung function. 24 females
with sporadic or TSC-LAM were enrolled in four different centres. Patients received everolimus at
2.5 mg·day−1 for 4 weeks, followed by dose titration to 5 mg·day−1 for 4 weeks then 10 mg·day−1 for
18 weeks. The safety profile of everolimus appeared similar to that of sirolimus in the MILES trial. The most
common adverse events were stomatitis and headache; other common adverse events were peripheral
oedema, diarrhoea, nausea, cough, oropharyngeal pain and fatigue. Four serious adverse events felt to be
related to the study drug were observed including pneumonia, pneumocystis and heart failure, which were
not observed in the MILES trial. VEGF-D levels decreased throughout the treatment period with most of the
reduction occurring within the first 8 weeks. Stability of FVC and improvement in FEV1, relative to baseline,
were found and a trend toward improvement in exercise capacity, as measured by increase in 6MWD from
baseline, was observed. The efficacy results after 26 weeks of treatment were compared with the 6-month
data in the placebo-controlled group from the MILES study showing a slightly larger increase in FEV1 and a
lower improvement in FVC than the absolute difference seen between sirolimus and placebo in the MILES
study. However, a difference between the patient populations including a greater number of Asian patients
and a greater severity of disease in the MILES placebo group may affect the comparison [136].
Currently, therapy with mTOR inhibitors in LAM is indicated in patients with abnormal lung function,
patients whose lung function is declining rapidly, and/or for the treatment of chylous effusions, large
angiomyolipomas and lymphangioleiomyomas (figs 4 and 5). The role of sirolimus in patients with
normal or stable lung function is unclear.
Future treatments
Although mTOR inhibitors are effective in stabilising lung function, reducing the size of angiomyolipomas
and controlling lymphatic complications, they are not curative, and the benefits are observed only during
FIGURE 4 Abdominal contrast- enhanced computed tomography image of a 39-year-old patient with a
biopsy-proven lymphangioleiomyoma and chylous ascites needing drainage. The lymphangioleiomyoma is evident
as a solid, paraortic, retroperitoneal mass, showing enhancement and low density, intra-lesion area (white
asterisk).
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the treatment period, with regain of disease-related symptoms and complications after cessation of therapy.
Recent advances in understanding the molecular pathogenesis of the disease have suggested new potential
targets for treatment of LAM.
Autophagy has recently been shown to be a critical component of TSC tumorigenesis. The combination of
mTORC1 and autophagy inhibition (using sirolimus and chloroquine) is more effective than either
treatment alone in inhibiting the survival of tuberin (TSC2)-null cells, growth of TSC2-null xenograft
tumours and the development of spontaneous renal tumours in Tsc2+/− mice [43]. Thus, dual inhibition of
mTORC1 and autophagy is a potential therapeutic strategy for patients with TSC and LAM. A phase 1
clinical trial on safety of the combined use of sirolimus and hydroxychloroquine in patients with LAM is
ongoing (Elizabeth Henske, Brigham and Women’s Hospital, Boston, MA, USA; personal communication).
As previously mentioned, MMPs are involved in pathogenesis of the disease. Thus, inhibition of MMPs is
considered a potential target in treatment of LAM. After the report of a case of significant clinical
improvement in association with a reduction of urinary MMPs after treatment with doxycycline by MOSES
et al. [116], the drug has been tested in an open label interventional study. 31 patients completed
12 months of treatment showing a significant mean decrease in FEV1 (70 mL), but no significant variation
in DLCO and 6MWD, and a significant reduction in urinary MMP-9 levels and serum MMP-2 levels but
no significant differences between pre- and post-treatment serum MMP-9 levels, suggesting a mechanism
of action different from MMP blockade [116]. In a double-blind, placebo-controlled clinical trial of
doxycycline, the mean decline in FEV1 per year did not differ between the placebo and the treatment
group, although the effect of doxycycline on urinary levels of MMP-9 was confirmed [100]. The results of
this study may have been limited by the small number of patients (n=15) who completed the 24 months
of treatment, due to a high percentage of withdrawals. Nonetheless, the authors conclude that the lack of
effect of the drug on any clinical outcome (FEV1, FVC, DLCO, total lung capacity, shuttle-walk distance or
quality of life scores) makes it unlikely that doxycycline has a useful effect in LAM.
Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme and thereby block geranylgeranylation of Rho GTPases
and farnesylation of Ras and Rheb [137]. Simvastatin was shown to inhibit RhoA GTPase activity and
proliferation of TSC-null cells and TSC2-null tumour growth in mice, and to promote apoptosis [49].
Treatment with sirolimus and simvastatin prevented recurrence of the tumours, even after discontinuation of
both drugs [49]. By contrast, atorvastatin failed to reduce the size of liver and renal tumours in a mouse
model of TSC [138]. In a mouse model of LAM, simvastatin prevented alveolar space enlargement and,
together with sirolimus, blocked MMP upregulation and alveolar destruction [139]. The use of different cell
types may explain the contradictory evidence regarding the efficacy of statins in these preclinical models.
Recently, the use of these drugs on the same TSC-null cells, showed the growth-inhibitory and proapoptotic
effects of simvastatin compared with atorvastatin [140]. A retrospective review of 335 patients with LAM
showed a significantly greater yearly rate of decline of DLCO % predicted in LAM patients on statins in
comparison with their matched controls [141]. However, in this study, the number of patients on simvastatin
was small and the patients were not given an mTOR inhibitor. The results of a retrospective analysis of
patients who were treated with sirolimus alone, or a combination of sirolimus and simvastatin, or simvastatin
alone because of hypercholesterolaemia have just been published [142]. Within the limitations of the study
design, combined therapy with sirolimus plus simvastatin did not result in a greater prevalence of adverse
events beyond those expected from the use of each one of the two drugs and simvastatin did not seem to
modify the beneficial effects of sirolimus therapy in LAM [142]. A phase 1–2 clinical trial on combination
a) b)
FIGURE 5 Abdominal magnetic resonance imaging of the same patient after 3 months of therapy with
sirolimus, showing complete resolution of the effusion and an initial volume reduction of the
lymphangioleiomyomas (white asterisk) in T2-weighted images (a) and T1-weighted contrast-enhanced
fat-suppressed images (b).
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therapy with mTOR inhibitors (everolimus and sirolimus) and simvastatin is currently underway (Vera
Krymskaya, University of Pennsylvania, Philadelphia, PA, USA; personal communication).
As a role for oestrogens in molecular pathogenesis of LAM has been postulated, therapeutic strategies
including anti-oestrogen therapy represent a future possibility. A potential new therapeutic approach consists
of suppressing oestrogen secretion with aromatase inhibitors, especially in post-menopausal women in
whom the adrenal glands are the main source of oestrogens [143]. Letrozole is an aromatase inhibitor
currently used to treat oestrogen receptor-positive breast cancer. A trial of aromatase inhibition in LAM
(TRAIL) is being conducted (Francis X. McCormack, University of Cincinnati, Cincinnati, OH, USA;
personal communication).
Recently, an integration of the mTOR and E2–ERK pathways in the pathogenesis of LAM has been seen
[63]. Combination therapy targeting the E2–ERK pathway and the mTORC1 pathway, for example using
an oestrogen receptor antagonist in combination with mTOR inhibition, may be effective for LAM.
It has been demonstrated that platelet-derived growth factor receptor β (PDGFRβ) is present and active in
human and murine TSC lesions [144, 145]. An inverse relationship between mTOR activation and
PDGFRβ levels in TSC-derived cells has also been shown [146]. In a preclinical model, nearly complete
tumour inhibition with a combination of rapamycin and imatinib targeting two distinct signalling
pathways (mTORC1 and PDGFRβ, respectively) has been observed, suggesting a rationale for the clinical
use of this combination therapy for TSC and LAM [147].
In recent decades great progress has been made, drawing a new picture of LAM, however, more efforts are
still needed to eliminate the disease. Challenging issues for the future include a better comprehension of
pathogenesis, including both canonical and non-canonical pathways and the role of oestrogen, and the
development of new biomarkers and new therapeutic approaches. A combination strategy targeting
different pathways represents a promising approach for management of this disease.
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